Skip to main content
CHUGAI PHARMACEUTICAL CO., LTD. logo

CHUGAI PHARMACEUTICAL CO., LTD. - Investor Relations & Filings

Listed IPO Mar 1956
Ticker · 4519 ISIN · JP3519400000 LEI · 529900T9LAII161DCN95 T Manufacturing
Open in API
Filings indexed 123 across all filing types
Latest filing 2025-03-28 AGM Information
Country JP Japan
Listing T 4519 · 7 venues

About CHUGAI PHARMACEUTICAL CO., LTD.

https://www.chugai-pharm.co.jp/english/

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Recent filings

Filing Released Lang Actions
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were made at the company's 114th Annual General Meeting (AGM) held on March 27, 2025. Section 2 details the resolutions, including dividend approval and the election/re-election of directors and auditors, along with the voting results (votes for, against, abstentions, and approval rates). This content perfectly matches the definition of reporting the results of a shareholder vote following a general meeting. The most specific code for this is 'DVA' (Declaration of Voting Results & Voting Rights Announcements). Although it relates to an AGM, the core purpose is reporting the *results* of the vote, not general AGM materials (AGM-R) or proxy solicitation (PSI).
2025-03-28 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director on March 27, 2025. The content details the resolution by the Board of Directors regarding the disposal of restricted stock compensation (譲渡制限付株式報酬制度) to directors, executive officers, and employees. This type of filing, which reports a specific, material corporate action (like a stock compensation plan implementation or significant financing event) outside of regular periodic reports (10-K, IR), is characteristic of a Japanese Extraordinary Report, which corresponds to the SEC's 8-K filing. Among the provided codes, 'CAP' (Capital/Financing Update) is relevant due to the stock disposal, but the structure and explicit mention of '臨時報告書' (Extraordinary Report) strongly suggest a filing made under specific Japanese regulations for material events. In the context of the provided definitions, this is a significant corporate action related to capital/compensation structure. Since the document explicitly details the terms of a stock compensation plan involving the issuance/disposal of shares (a form of capital change/financing activity) and is filed as an 'Extraordinary Report' (which often covers material events not covered by other specific codes), 'CAP' (Capital/Financing Update) is the most fitting category describing the *substance* of the filing, although 'RNS' (Regulatory Filings) is a close fallback for non-US specific regulatory forms. Given the detailed nature of the stock disposal terms, 'CAP' is chosen over the general 'RNS'.
2025-03-27 Japanese
内部統制報告書－第114期(2024/01/01－2024/12/31)
Governance Information Classification · 100% confidence The document explicitly states its nature in the header section: "【提出書類】 内部統制報告書" (Document Submitted: Internal Control Report) and cites the legal basis "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). The content discusses the framework, scope, criteria, and conclusion regarding the assessment of internal controls over financial reporting ("財務報告に係る内部統制"). This directly corresponds to the requirements for an Internal Control Report, which is a mandatory filing in Japan, often associated with the annual reporting cycle but distinct from the full 10-K or a general Audit Report (AR). Since there is no specific code for a Japanese 'Internal Control Report' among the provided options, I must select the closest fit based on the content's focus on auditing/controls or general reporting. The content is a formal report detailing internal control assessment, which aligns most closely with the scope of an Audit Report/Information (AR), as it involves an assessment of controls, although it is specifically an 'Internal Control Report' (J-SOX related). Given the options, AR is the best fit for a formal control assessment report that is not the full annual report (10-K). However, the document is a formal, comprehensive report, not just an announcement of one. In the context of US filings, this is often part of the 10-K, but as a standalone Japanese filing, it is a specific control report. Since 'AR' covers 'Stand-alone audit reports, applied accounting principles, and results of internal or regulatory stress tests', this formal internal control assessment fits best under AR.
2025-03-27 Japanese
確認書
Audit Report / Information Classification · 98% confidence The document is a confirmation statement (確認書) submitted to the Kanto Local Finance Bureau Director (関東財務局長) on March 27, 2025, by Chugai Pharmaceutical Co., Ltd. The core content involves the CEO (奥田修) and CFO (谷口岩昭) confirming that the contents of the company's Securities Report (有価証券報告書) for the fiscal year ended December 31, 2024, are appropriate based on the Financial Instruments and Exchange Act. A Securities Report in Japan is the equivalent of the US SEC's 10-K filing. Since this document is a confirmation *of* the Securities Report, and not the report itself, it is a regulatory filing related to the annual reporting cycle. Given the specific nature of confirming the accuracy of the annual report (which is the 10-K equivalent), and the lack of a specific code for 'Securities Report Confirmation', the most appropriate classification is the general 'Regulatory Filings' (RNS) as a fallback for specific regulatory confirmations that aren't explicitly listed, or potentially related to the 10-K process. However, since the document explicitly references the '有価証券報告書' (Securities Report), which is the Japanese equivalent of the 10-K, and this confirmation is a mandatory step related to that filing, I will check if any other code fits better. None of the provided codes perfectly match 'Securities Report Confirmation'. Given its regulatory nature and short length (under 5000 chars), RNS is the safest fallback. If the document *was* the actual Securities Report, it would be 10-K. Since it is a confirmation document, RNS is the best fit among the options provided for miscellaneous regulatory documents. FY 2024
2025-03-27 Japanese
有価証券報告書－第114期(2024/01/01－2024/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains comprehensive financial data, management indicators, and business information for the fiscal year ending December 31, 2024. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2024
2025-03-27 Japanese
2024年12月期決算短信〔ＩＦＲＳ〕（連結）
Regulatory Filings
2025-01-30 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.